Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours

The FDA-approved starting dosage of capecitabine is 1,250 mg/m(2), and market research indicates that U.S. physicians routinely prescribe 1,000 mg/m(2). Retrospective analyses however report reduced toxicity and efficacy in a subset of patients with the 3R/3R genotype of the thymidylate synthase gen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Soo, Ross Andrew, Syn, Nicholas, Lee, Soo-Chin, Wang, Lingzhi, Lim, Xn-Yii, Loh, Marie, Tan, Sing-Huang, Zee, Ying-Kiat, Wong, Andrea Li-Ann, Chuah, Benjamin, Chan, Daniel, Lim, Siew-Eng, Goh, Boon-Cher, Soong, Richie, Yong, Wei-Peng
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4906519/
https://ncbi.nlm.nih.gov/pubmed/27296624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep27826
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados